196 related articles for article (PubMed ID: 12830007)
1. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Pomier-Layrargues G; Paquin SC; Hassoun Z; Lafortune M; Tran A
Hepatology; 2003 Jul; 38(1):238-43. PubMed ID: 12830007
[TBL] [Abstract][Full Text] [Related]
2. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
3. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
4. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
[TBL] [Abstract][Full Text] [Related]
5. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial.
Ottesen LH; Aagaard NK; Kiszka-Kanowitz M; Rehling M; Henriksen JH; Pedersen EB; Flyvbjerg A; Bendtsen F
Hepatology; 2001 Sep; 34(3):471-7. PubMed ID: 11526531
[TBL] [Abstract][Full Text] [Related]
6. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
Péron JM; Bureau C; Gonzalez L; Garcia-Ricard F; de Soyres O; Dupuis E; Alric L; Pourrat J; Vinel JP
Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
[TBL] [Abstract][Full Text] [Related]
8. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
Watson D; Grover R; Anzueto A; Lorente J; Smithies M; Bellomo R; Guntupalli K; Grossman S; Donaldson J; Le Gall JR;
Crit Care Med; 2004 Jan; 32(1):13-20. PubMed ID: 14707555
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
Skagen C; Einstein M; Lucey MR; Said A
J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
[TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison.
Baik SK; Jeong PH; Ji SW; Yoo BS; Kim HS; Lee DK; Kwon SO; Kim YJ; Park JW; Chang SJ; Lee SS
Am J Gastroenterol; 2005 Mar; 100(3):631-5. PubMed ID: 15743362
[TBL] [Abstract][Full Text] [Related]
13. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Guevara M; Ginès P; Fernández-Esparrach G; Sort P; Salmerón JM; Jiménez W; Arroyo V; Rodés J
Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
[TBL] [Abstract][Full Text] [Related]
14. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Gülberg V; Bilzer M; Gerbes AL
Hepatology; 1999 Oct; 30(4):870-5. PubMed ID: 10498636
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.
Kiser TH; Fish DN; Obritsch MD; Jung R; MacLaren R; Parikh CR
Nephrol Dial Transplant; 2005 Sep; 20(9):1813-20. PubMed ID: 15956066
[TBL] [Abstract][Full Text] [Related]
17. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Katsaraki A; Tsianos EV
Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
[TBL] [Abstract][Full Text] [Related]
18. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study.
Chen HH; Sundt TM; Cook DJ; Heublein DM; Burnett JC
Circulation; 2007 Sep; 116(11 Suppl):I134-8. PubMed ID: 17846293
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of octreotide in patients with hepatic cirrhosis.
McCormick PA; Chin J; Greenslade L; Karatapanis S; Dick R; McIntyre N; Burroughs AK
Hepatology; 1995 May; 21(5):1255-60. PubMed ID: 7737631
[TBL] [Abstract][Full Text] [Related]
20. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1--effect on survival?
Gülberg V; Gerbes AL
Z Gastroenterol; 2002 Sep; 40(9):823-6. PubMed ID: 12215953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
